# Abbvie (ABBV) — Analyst Forecast

ABBV · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/abbv/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 24 | 7 | 1 | 32 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $247.00 | $291.13 | $320.00 | 16 |

Last price $281.12 (as of Oct 13, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 9, 2026 | Guggenheim | Maintained | Buy | $288.00 |
| Oct 9, 2026 | UBS | Maintained | Neutral | $275.00 |
| Oct 8, 2026 | Cantor Fitzgerald | Maintained | Overweight | $290.00 |
| Oct 8, 2026 | JP Morgan | Maintained | Overweight | $300.00 |
| Oct 7, 2026 | Morgan Stanley | Maintained | Overweight | $310.00 |
| Oct 6, 2026 | Scotiabank | Maintained | Sector Outperform | $320.00 |
| Sep 10, 2026 | HSBC | Maintained | Buy | $315.00 |
| Aug 20, 2026 | Piper Sandler | Maintained | Overweight | $303.00 |
| Aug 17, 2026 | Wells Fargo | Maintained | Overweight | $300.00 |
| Aug 13, 2026 | Wolfe Research | Upgraded | Peer Perform → Outperform | $300.00 |
| Aug 11, 2026 | BNP Paribas | Maintained | Neutral | $247.00 |
| Aug 10, 2026 | Evercore ISI Group | Maintained | Outperform | $260.00 |
| Aug 4, 2026 | Guggenheim | Maintained | Buy | $288.00 |
| Aug 3, 2026 | Cantor Fitzgerald | Maintained | Overweight | $285.00 |
| Aug 3, 2026 | Canaccord Genuity | Maintained | Buy | $290.00 |
| Jul 29, 2026 | Barclays | Maintained | Overweight | $300.00 |
| Jul 22, 2026 | Canaccord Genuity | Maintained | Buy | $282.00 |
| Jul 15, 2026 | Citigroup | Maintained | Neutral | $260.00 |
| Jul 13, 2026 | BMO Capital | Maintained | Outperform | $300.00 |
| Jul 13, 2026 | UBS | Maintained | Neutral | $260.00 |

## Frequently Asked Questions

### What is the price target for ABBV stock?

The average 12-month analyst price target for Abbvie (ABBV) is $291.13, with a high estimate of $320.00 and a low of $247.00, across 16 analysts.

### Is ABBV a buy, sell, or hold?

Analysts covering Abbvie currently average a Buy rating: 24 buy, 7 hold and 1 sell, from 32 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for ABBV?

The average price target of $291.13 implies 3.56% upside from the last price of $281.12.

### What is the latest analyst rating on ABBV?

On Oct 9, 2026, Guggenheim maintained Abbvie at Buy with a price target of $288.00.

## Similar Stocks

- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [ABT](https://www.lighthorse.io/tickers/abt) — Abbott Laboratories Common Stock
- [JNJ](https://www.lighthorse.io/tickers/jnj) — Johnson & Johnson Common Stock
- [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock
- [BMY](https://www.lighthorse.io/tickers/bmy) — Bristol-Myers Squibb Company Common Stock
- [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new)
- [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock
- [GILD](https://www.lighthorse.io/tickers/gild) — Gilead Sciences, Inc. - Common Stock
- [AZN](https://www.lighthorse.io/tickers/azn) — AstraZeneca PLC Ordinary Shares
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).